(Q43136756)

14 November 2017

title

Prolonged inhibition of glycogen phosphorylase in livers of Zucker Diabetic Fatty rats models human glycogen storage diseases (English)

1 reference

14 November 2017

Eike Floettmann

1

1 reference

14 November 2017

Laraine Gregory

2

1 reference

14 November 2017

Joanne Teague

3

1 reference

14 November 2017

John Myatt

4

1 reference

14 November 2017

Clare Hammond

5

1 reference

14 November 2017

Simon M Poucher

6

1 reference

14 November 2017

Huw B Jones

7

1 reference

14 November 2017

language of work or name

English

0 references

publication date

9 March 2010

1 reference

14 November 2017

published in

Toxicologic Pathology

1 reference

14 November 2017

volume

38

1 reference

14 November 2017

issue

3

1 reference

14 November 2017

page(s)

393-401

1 reference

Increased lipogenesis and resistance of lipoproteins to oxidative modification in two patients with glycogen storage disease type 1a.

14 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0192623310362707

Role of liver in pathophysiology of NIDDM

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623310362707

Pathogenesis of NIDDM. A balanced overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623310362707

Sensitivity of glycogen phosphorylase isoforms to indole site inhibitors is markedly dependent on the activation state of the enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623310362707

Liver disease in patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623310362707

Glycogen phosphorylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623310362707

Hepatic carbon flux after re-feeding in the glycogen-storage-disease (gsd/gsd) rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623310362707

Clinical resolution of glycogenic hepatopathy following improved glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623310362707

Histopathologic approach to metabolic liver disease: Part 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623310362707

Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623310362707

Glycogen storage disease, types I to X: criteria for morphologic diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623310362707

Hepatic glycogenosis: reversible hepatomegaly in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623310362707

Glycogen storage diseases: new perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623310362707

Effect of subchronic exposure to malathion on glycogen phosphorylase and hexokinase activities in rat liver using native PAGE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623310362707

Glycogen storage disease: clinical, biochemical, and molecular heterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623310362707

Glycogen phosphorylase inhibitors for treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623310362707

Glycogen storage diseases in animals and their potential value as models of human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623310362707

Glycogen storage diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623310362707

21 January 2018

Identifiers

DOI

10.1177/0192623310362707

1 reference

14 November 2017

1 reference